Yinjie Zhu

Yinjie Zhu

Auto-generated profile, based on publicly available information

Yinjie Zhu

Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
XZXi Zhang
Xi Zhang
BXBinbin Xia
Binbin Xia
HZHong Zheng
Hong Zheng
JNJie Ning
Jie Ning
YZYinjie Zhu
Yinjie Zhu
HGHongchang Gao
Hongchang Gao
Background: Prostate cancer (PCa) is the second most prevalent cancer in males worldwide, yet detecting PCa and its metastases remains a major challenging task in clinical research setups. The present study aimed to characterize the metabolic changes underlying the PCa progression and investigate the efficacy of related metabolic panels for an accurate PCa assessment.Methods: In the present study, 75 PCa subjects, 62 PCa patients with bone metastasis (PCaB), and 50 benign prostatic hyperplasia (BPH) patients were enrolled, and we performed a cross-sectional metabolomics analysis of serum samples collected from these subjects using a1H nuclear magnetic resonance (NMR)-based metabolomics approach.Results: Multivariate analysis revealed that BPH, PCa, and PCaB groups showed distinct metabolic divisions, while univariate statistics integrated with variable importance in the projection (VIP) scores identified a differential metabolite series, which included energy, amino acid, and ketone body metabolism. Herein, we identified a series of characteristic serum metabolic changes, including decreased trends of 3-HB and acetone as well as elevated trends of alanine in PCa patients compared with BPH subjects, while increased levels of 3-HB and acetone as well as decreased levels of alanine in PCaB patients compared with PCa. Additionally, our results also revealed the metabolic panels of discriminant metabolites coupled with the clinical parameters (age and body mass index) for discrimination between PCa and BPH, PCaB and BPH, PCaB and PCa achieved the AUC values of 0.828, 0.917, and 0.872, respectively.Conclusions: Overall, our study gave successful discrimination of BPH, PCa and PCaB, and we characterized the potential metabolic alterations involved in the PCa progression and its metastases, including 3-HB, acetone and alanine. The defined biomarker panels could be employed to aid in the diagnosis and classification of PCa in clinical practice.

27 October 2023 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
RCRuohua Chen
Ruohua Chen
YNYee Ling Ng
Yee Ling Ng
XYXinlan Yang
Xinlan Yang
YZYinjie Zhu
Yinjie Zhu
LLLianghua Li
Lianghua Li
JLJianjun Liu
Jianjun Liu

10 March 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YSYiping Shi
Yiping Shi
LXLian Xu
Lian Xu
YZYinjie Zhu
Yinjie Zhu
YWYining Wang
Yining Wang
RCRuohua Chen
Ruohua Chen
JLjianjun liu
jianjun liu
Purpose: Differentiating lymph node metastases (LNM) from peripheral ganglia by physiological prostate-specific membrane antigen (PSMA) uptake is challenging. Two tracers (68Ga-PSMA-11 and 18F-fluorodeoxyglucose [FDG]) metabolic uptake patterns were evaluated by positron emission tomography-computed tomography (PET-CT), searching for differences that could tell ganglia from LNM.Methods: Dual 68Ga-PSMA-11 and 18F-FDG PET-CT data of 138 prostate cancer patients acquired from June 2018 to December 2019 were retrospectively evaluated. Ganglia and LNM with PSMA-11 uptake above local background were analyzed by the location and PSMA-11-PET and FDG-PET maximum standardized uptake value (SUVmax).Results: PSMA-11-positive ganglia (n = 381) and LNM (n = 83) were identified in 138 and 58 patients, respectively. The LNM SUVmax of PSMA-11-PET (16.4 ± 14.8 vs 2.3 ± 0.7, P < 0.001) and FDG-PET (3.3 ± 3.2 vs 1.5 ± 0.5, P < 0.001) were higher than in ganglia. The probabilities of being an LNM in the low-potential (PSMA-11-PET SUVmax of <4.1 and FDG-PET SUVmax of 4.1 and FDG-PET SUVmax of <2.05, or PSMA-11-PET SUVmax of 2.05), and high-potential (PSMA-11-PET SUVmax of >4.1 and FDG-PET SUVmax of >2.05) groups were 0.9% (3/334), 44.6% (37/83), and 91.5% (43/47), respectively (P < 0.001). The cervical and coeliac ganglia had higher PSMA-11 and FDG uptake than the sacral ganglia (P < 0.001 for all). LNM PSMA-11 and FDG uptake was similar in these three locations.Conclusion: The FDG-PET and PSMA-11-PET SUVmax, especially when combined, could well differentiate LNM from ganglia. The tracers uptake differed between cervical/coeliac and sacral ganglia, so the lesion location should be considered during image assessment.

22 August 2025 in Turkish Journal of Physical Medicine and Rehabilitation
Verified
Journal Article
Open access
YMYe-Ran Mao
Ye-Ran Mao
WFWenjun Fan
Wenjun Fan
YZYinjie Zhu
Yinjie Zhu
QGQing Gu
Qing Gu
QJQuanfang Jin
Quanfang Jin
ZLZhidan Liu
Zhidan Liu
Objectives: The objective of study was to compare the effects of pelvic myofascial trigger point release and structured pelvic floor muscle training (PFMT) in patients with female sexual dysfunction after vaginal delivery. Patients and methods: In this prospective randomized controlled trial, 126 patients with female sexual dysfunction after vaginal delivery were included between October 2022 and December 2023. The participants were randomly allocated to receive either trigger point release and structured PFMT (63 females; mean age, 30.4±2.8 years; range, 25 to 35 years) or only structured PFMT (63 females; mean age, 31.4±3.1 years; range, 24 to 35 years). The primary outcome was Female Sexual Function Index (FSFI) score of the participants. Secondary outcomes were Glazer pelvic floor electromyography and the Visual Analog Scale score of urogenital pain map, pelvic floor muscle pain map, and bladder pain map. Results: The observation group manifested a significant improvement in the FSFI total score and each individual subitem compared to the control group (p<0.01). In addition, in Glazer pelvic floor electromyography, the observation group exhibited a significant decrease in pre-resting value and post-resting value compared to the control group after treatment (p<0.01). Additionally, there was significant decrease in Visual Analog Scale scores in the observation group compared to the control group (p<0.01). Moreover, after therapy, the observation group demonstrated a significantly greater enhancement in pelvic floor muscle strength than the control group (p<0.05). Conclusion: Pelvic myofascial trigger point release combined with structured PFMT is an efficient treatment for female sexual dysfunction after vaginal delivery compared to structured PFMT alone.